The ClearCell® FX1 System, driven by the CTChip® FR, is one of the world’s first automated cell retrieval systems that can enrich wholly intact and viable Circulating Tumour Cells (CTCs) from small amounts of blood in a relatively short time.
Combined with the high levels of purity, the CTCs are enriched in suspension, which allows for easy integration with downstream molecular analyses and diagnostic assays. This means that researchers and clinicians can use these insights to provide timely, tailored treatment options.
More than 80% of all cancer patients die from metastasis, not the actual primary tumour. Cancer is complex, heterogeneous and dynamic. For the patient, a cancer treatment journey drains physically, emotionally, mentally and financially. For the oncologist, it may mean questions of possible overtreatment and having to subject patients to frequent, painful biopsies. Over the course of treatment, the cancer can evolve and become resistant, making treatment decisions challenging and potentially sub-optimal.
Therefore the ability to precisely detect these changes facilitates timely diagnosis and staging of the disease; this ability is critical for precise, tailored treatment and proactive monitoring. This is where Circulating Tumour Cells (CTCs) become critically relevant.
Significance of CTCs
Circulating Tumour Cells (CTCs) are extremely rare cells that have detached from solid tumours, travel in the bloodstream and can cause the cancer to spread. They are considered the seeds of metastasis and could be a clear indication of disease progression.
A blood test, or liquid biopsy that can detect and profile these CTCs presents a quick, non-invasive way to obtain real-time information about the cancer disease status. In combination with other diagnostic methods, doctors may be able to design specific responses to fight the diagnosed cancer.
Combining this insight with the ability to match drugs according to disease mutation and resistance, isolating wholly intact CTCs could be the potential gold standard for the detection of cancer metastasis.
All from a simple blood draw.
Our Technology to help
Fully automated and entirely label-free, Clearbridge BioMedics’ ClearCell® FX1 System, with the patented microfluidic biochip, CTChip® FR1, the ClearCell® FX1 System achieves label-free CTC enrichment that better addresses the dynamic and complex nature of cancer. It even provides the potential for serial real-time treatment monitoring.
|ClearCell® FX1 System
Cell Culture Automation
ClearCell® FX1 Unit x 1
ClearCell® FX1 Installation Run Kit x 1
FX System Warranty (1st year)
Fluorescence In Situ Hybridisation (FISH)
Fluorescence in situ hybridisation (FISH) is an established cytogenetic technique used in pathology laboratories for tumour profiling and screening of genetic aberrations, such as gene translocation, amplification and deletions. It is also the current gold standard for selection of cancer patient eligible for HER2 and ALK targeted drug therapy. …
The emergence of novel technologies offers a new avenue to obtain circulating tumour cells (CTCs) for understanding metastasis. CTCs are extremely rare in circulation and the isolation of intact and viable cells is non-trivial. Use of affinity based methods and magnetic beads based methods could potentially impact cellular phenotypes and viability …
KRAS is an oncogene with extremely high incidence of mutations. KRAS mutations have been seen in approximately 25% of all cancer types and 30-40% of colorectal cancer (Arrington et al. 2012). It is also associated with poorer prognosis and treatment response in colorectal and lung cancer. As such, there is significant interest in molecular testing of KRAS mutation. …
Immunofluorescence (IF) / Immunocytochemistry (ICC)
This application note describes the label-free enrichment of CTCs or microemboli from blood sample using the ClearCell® FX platform followed by immunofluorescence assay
Contact Us at email@example.com for more information.